Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05076370 · ClinicalTrials.gov registry record · Early Phase 1
Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine
A Early Phase 1 study of Addiction, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT05076370 is a Early Phase 1 study of Addiction that has completed, run by Yale University. The registered enrollment target is 7 participants, below the 692-participant average among 16 other Addiction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05076370, a Early Phase 1 study of Addiction, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving methadone or buprenorphine.
Conditions Studied
Interventions
- DRUG CBD Day 1
- DRUG CBD Day 2
- DRUG CBD Day 3
Study Locations (1)
Connecticut
- Veteran Affairs Hospital - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2024-06-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05076370
The ClinicalTrials.gov registry entry for NCT05076370 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 692-participant average among 16 other Addiction trials with a reported enrollment target (99% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Addiction appearing as the primary indexed condition, and to 3 interventions - of which CBD Day 1 is the first listed.
NCT05076370 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05076370 about?
NCT05076370 is a clinical study titled "Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine". The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effect...
What is the current status of trial NCT05076370?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2021-12-08. Estimated completion is 2024-06-28.
What conditions does trial NCT05076370 study?
This clinical trial studies the following conditions: Addiction.
What interventions are being tested in trial NCT05076370?
The interventions under investigation include: CBD Day 1 (DRUG), CBD Day 2 (DRUG), CBD Day 3 (DRUG).
Who is sponsoring clinical trial NCT05076370?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05076370 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing the Abuse Liability of Prescription Opioids
COMPLETED · Early Phase 1
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
-
Tdcs And cogNitive traininG cOmbined for AUD (TANGO)
RECRUITING · NA
-
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics
RECRUITING
-
Behavioral and Functional Task Development, Implementation, and Testing
RECRUITING · NA
-
Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.